DDInter1925 DDInter1376
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Vemurafenib {u} (Compound) resembles {v} (Compound) Etoricoxib
Vemurafenib {u} (Compound) treats {v} (Disease) skin cancer
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
Vemurafenib {u} (Compound) upregulates {v} (Gene) DHRS12
Vemurafenib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Vemurafenib {u} (Compound) downregulates {v} (Gene) CLPP
Vemurafenib {u} (Compound) causes {v} (Side Effect) Eosinophilia
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Vemurafenib (Compound) resembles Etoricoxib (Compound)
Vemurafenib (Compound) treats skin cancer (Disease)
Vemurafenib (Compound) binds CYP3A4 (Gene)
Vemurafenib (Compound) upregulates DHRS12 (Gene)
Vemurafenib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Vemurafenib (Compound) downregulates CLPP (Gene)
Vemurafenib (Compound) causes Eosinophilia (Side Effect)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan